Observational studies may over- or under-estimate SARS-CoV-2 vaccine effectiveness (VE) depending on whether healthier (i.e. healthy vaccine effect (HVE)) or more ill individuals are preferentially vaccinated. To evaluate this issue, we compared non-COVID-19 mortality in vaccinated versus unvaccinated individuals. This is a nationwide retrospective observational study in the entire adult population in Austria with previously documented SARS-CoV-2 infection with a follow-up from 2021 to 2023. Cox regression analyses were used to calculate hazard ratios (HRs) according to the number of SARS-CoV-2 vaccinations. We also performed matched analyses, where on each day, newly vaccinated individuals were matched with unvaccinated individuals based on age, sex and nursing home residency. In 4,324,485 eligible individuals, differences in non-COVID-19 mortality risk between vaccinated and unvaccinated were most prominent in the early periods and decreased thereafter. Matched analyses for the first two weeks after vaccination showed HRs below 0.5 for vaccinated versus unvaccinated individuals irrespective of vaccination numbers. Similar findings were retrieved for non-COVID-19, all-cause, and cancer deaths. Overall, COVID-19 deaths were significantly reduced in vaccinated individuals (VE of 26 to 53%). HVE for SARS-CoV-2 vaccines was strong early after vaccination and diminished over time. HVE should be considered when estimating VE.
18 February 2025 in The Journal of Infectious Diseases
Background: Postpandemic surveillance data on coronavirus disease 2019 (COVID-19) infections may help inform future public health policies regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, vaccinations, or other COVID-19 measures. We estimate the total SARS-CoV-2 infections in Austria after the end of the pandemic from wastewater data and utilize these estimates to calculate the average national levels of SARS-CoV-2 infection protection and COVID-19 death protection. Methods: We estimated the total SARS-CoV-2 infections in Austria after the end of the pandemic (5 May 2023, per World Health Organization) up to May 2024 from wastewater data using a previously published model. These estimates were used in an agent-based model (ABM) to estimate average national levels of SARS-CoV-2 infection protection and COVID-19 death protection, based on waning immunity estimates of infections and vaccination in previous literature. Results: We estimate approximately 3.2 million infections between 6 May 2023 and 23 May 2024, with a total of 17.8 million infections following 12 May 2020. The ABM estimates that the national average death protection was approximately 82% higher in May 2024 than before the pandemic. This represents a relative decrease of 8% since May 2023. It also shows that 95% of people in Austria were infected with SARS-CoV-2 at least once by May 2024. National infection protection remained relatively low after the onset of Omicron. Conclusions: These findings should be considered for public health decisions on SARS-CoV-2 testing practices and vaccine booster administrations.
10 February 2025 in Journal of Infection and Public Health
Comprehensive analyses of COVID-19 case fatality rates (CFRs) and infection fatality rates (IFRs) that span the entire pandemic are not yet available but critical to retrospectively evaluate the COVID-19 disease burden and its related public health policies. We used nationwide individual participant data from Austria, the continental country with the highest SARS-CoV-2 testing rate per capita, to calculate COVID-19 CFR and estimate IFR covering the entire pandemic. This retrospective observational study included all Austrian residents and covered the time from February 2020 to May 2023, examining CFRs overall, monthly, and during dominant SARS-CoV-2 variant periods. CFRs were calculated for the whole population and stratified according to immunization status (presence of previous vaccination and/or infection), age, gender and nursing home residency. We additionally estimated the IFRs based on estimations of undocumented infections using a test positivity model. The overall CFR of 30-day COVID-19 mortality was 0.31 % but varied depending on month, with the highest being 5.9 % in April 2020 and the lowest 0.07 % in January 2022. The variant periods reflected this trend of decreasing CFR, with the highest for Wuhan-Hu-1 (2.05 %) and the lowest for BA.1 (0.08 %). Overall CFRs were particularly high in the group without any previous immunizing event (0.67 %), the elderly (85 + year group: 7.88 %) and in nursing home residents (7.92 %). Nursing home residents accounted for 30.82 % of all COVID-19 deaths while representing only 1.22 % of diagnosed infections. Total SARS-CoV-2 infections were estimated to be almost double than confirmed cases with a corresponding overall IFR of 0.16 %. This estimation of nationwide CFR and IFR across the entirety of the SARS-CoV-2 pandemic gives crucial insights into the period-dependent variability of the severity of diagnosed COVID-19 cases and its risk factors. Our findings further underline the disproportionate severity of COVID-19 among the elderly and especially nursing home residents.
Background/Objectives: An Endocrine Society Clinical Practice Guideline on vitamin D was published in 2024. Its main objective was the use of vitamin D to lower the risk of disease in individuals without established indications for vitamin D treatment or 25-hydroxavitamin D (25(OH)D) testing. The methodology followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and the Evidence-to-Decision (EtD) framework. Evidence from randomized controlled trials (RCTs) retrieved by a systematic review was prioritized to inform this guideline. It was concluded that vitamin D supplementation reduces rickets and respiratory tract infections in children, mortality in individuals aged 75 years or older, pregnancy complications (outcomes), and progression of prediabetes to diabetes mellitus. Consequently, empiric vitamin D supplementation was recommended for individuals aged 1 to 18 years and ≥75 years, pregnant women, and individuals with prediabetes. Empiric vitamin D supplementation is defined as a vitamin D intake that exceeds the Dietary Reference Intakes (DRIs) and is implemented without 25(OH)D testing. Methods: This article provides a comprehensive guideline summary and critical appraisal based on a narrative review on scientific publications regarding that guideline. Results: Several publications discussed the 2024 Endocrine Society Clinical Practice Guideline on vitamin D. The main criticisms and discussion relate to unclear vitamin D dosages, guideline applicability to certain populations including controversy with previous vitamin D guidelines, and the implications of 25(OH)D testing. Conclusions: The 2024 Endocrine Society Clinical Practice Guideline on vitamin D followed a rigorous methodological approach with high quality standards but it leaves many open questions and uncertainties warranting clarification.
Adaptation of SARS-CoV-2 policies requires information on contemporary infection trends. As SARS-CoV-2 infections are no longer actively tracked, indirect measures such as estimations based on wastewater data are needed. This is a retrospective observational study. We estimated total SARS-CoV-2 infections in the entire population of Austria from April 1, 2024, to March 31, 2025, based on wastewater monitoring data. The applied method builds on a previously published approach that estimated infection prevalence during the pandemic by fitting wastewater measurements to seroprevalence data. Between April 1, 2024, and March 31, 2025, we estimate 2.5 million new infections in Austria. Active infections peaked at 337,000 in late September and decreased thereafter. Infection rates in winter were substantially lower compared to previous years. The findings indicate the earliest annual fall/winter peak and the lowest annual infections since 2020. Policy makers, physicians and high-risk individuals should be aware of the ongoing seasonal SARS-CoV-2 infection waves and their variability in timing.